■大麻二酚(CBD)是一种来自大麻植物的非精神活性植物大麻素。CBD在受体位点表现出各种相互作用,促使人们研究其潜在的抗炎作用,免疫调节,心理,和止痛效果。这项研究旨在调查生理,生物化学,和特定品牌的心理测量效应,在12周的观察期内,健康成年人中的大麻衍生的CBD产品。
■从东南大学招募的54名健康男性和女性(年龄=25±7岁;BMI=24.82±3.25kg/m2)完成了这项研究。参与者在禁食>8小时后到达实验室,和>48小时没有饮酒和剧烈运动。基线测量后(高度,体重,血压,心电图(ECG),和血液工作),参与者按性别分层,随机分为CBD组和安慰剂组.产品双盲给药,两者都以含有中链甘油三酯油的液体形式给出,而CBD产品特别含有50mg/mL的CBD。参与者被指示每天两次消耗1mL他们的产品,并且给予足够的产品以持续到他们的下一次实验室访问。在基线和第30±3、60±3和90±3天收集数据。抽取血液用于免疫和炎症生物标志物的分析。根据基础疼痛指数(FPI)使用尿液样本计算参与者的慢性疼痛。使用了自我报告的心理测量问卷(科恩的感知压力量表,匹兹堡睡眠质量指数,情绪状态简介,感知疼痛的10项李克特量表)评估压力,睡眠质量,情绪状态,和身体不适。为了确定总体福祉,参与者完成了每日调查,表明他们是否因疾病而缺勤或上学。计算每个测量的基线变化,和混合效应模型用于确定各组之间随时间的差异,同时调整基线值(α=0.05)。数据表示为平均值±标准偏差。
■对于免疫或炎症生物标志物没有分组-时间相互作用或分组或时间主效应(p>0.05)。分析显示,没有观察到对感知压力的逐组交互或主要影响,睡眠质量,整体情绪障碍,和所有情绪状态分量表的概况(p>0.05),除了“活力活动”。“活力活动”的子得分具有时间主效应(p=0.007;CBD前=19.5±5.2,CBD后=17.3±5.3;PL前=19.0±5.7,PL后=17.9±7.1),从访问3到访问4(p=0.025)和从访问3到访问5(p=0.014)下降。FPI有群体主要效应(p=0.028;前CBD=11.9±14.4,后CBD=8.8±10.9;前PL=9.0±14.2,后PL=12.9±11.5),这表明与CBD组相比,安慰剂组的疼痛增加更大。“感冒或流感”的发生率和患病率在各组之间没有显着差异(p>0.05)。
■CBD在健康成年人中是安全且耐受性良好的。这些发现表明CBD组的疼痛较低,这表明对CBD的消费有潜在的积极影响。“活力活动”在整个干预期间下降,这可能是学期的混淆效应。虽然选择的剂量是安全的,可能需要使用更高剂量的更多研究,因为可能需要这些研究来观察健康人群的进一步治疗效果.
UNASSIGNED: Cannabidiol (CBD) is a non-psychoactive phyto-cannabinoid derived from the Cannabis sativa plant. CBD exhibits various interactions at receptor sites, prompting the research of its potential anti-inflammatory, immunomodulatory, psychological, and pain-relieving effects. This
study aimed to investigate the physiological, biochemical, and psychometric effects of a brand-specific, hemp-derived CBD product in healthy adults over a 12-week observation period.
UNASSIGNED: 54 healthy males and females (age = 25 ± 7y; BMI = 24.82 ± 3.25 kg/m2) recruited from a large Southeastern University completed the
study. Participants arrived at the laboratory after > 8 h of fasting, and > 48 h without alcohol consumption and vigorous exercise. Following baseline measurements (height, weight, blood pressure, electrocardiogram (ECG), and blood work), participants were stratified by sex and randomized to either CBD or placebo groups. Products were administered double-blinded, with both given in liquid form containing medium-chain triglyceride oil, while the CBD product specifically contained 50 mg/mL of CBD. Participants were instructed to consume 1 mL of their product twice daily and were given enough product to last until their next laboratory visit. Data were collected at baseline and on days 30 ± 3, 60 ± 3, and 90 ± 3. Blood was drawn for analysis of immune and inflammatory biomarkers. Chronic pain among participants was calculated using urine samples according to the foundational pain index (FPI). Self-reported psychometric questionnaires were utilized (Cohen\'s Perceived Stress Scale, Pittsburgh Sleep Quality Index, Profile of Mood States,10-item Likert scale for perceived pain) to assess stress, sleep quality, mood state, and body discomfort. To determine overall wellbeing, participants completed a daily survey indicating if they missed work or school due to illness. Change from baseline was calculated for each measure, and mixed effects models were used to determine differences between groups over time while adjusting for baseline values (α = 0.05). Data are presented as mean ± standard deviation.
UNASSIGNED: There were no Group-by-Time interactions or Group or Time main effects for immune or inflammatory biomarkers (p > 0.05). Analyses revealed no Group-by-Time interactions or main effects observed for perceived stress, sleep quality, overall mood disturbance, and all the profile of mood state subscales (p > 0.05), except \"vigor-activity.\" A Time main effect was found for the sub-score for \"vigor-activity\" (p = 0.007; Pre CBD = 19.5 ± 5.2, Post CBD = 17.3 ± 5.3; Pre PL = 19.0 ± 5.7, Post PL = 17.9 ± 7.1), which decreased from Visit 3 to Visit 4 (p = 0.025) and from Visit 3 to Visit 5 (p = 0.014). There was a Group main effect for FPI (p = 0.028; Pre CBD = 11.9 ± 14.4, Post CBD = 8.8 ± 10.9; Pre PL = 9.0 ± 14.2, Post PL = 12.9 ± 11.5), indicating that the placebo group had greater increases in pain over the intervention compared to the CBD group. No significant differences were found between groups in the incidence and prevalence of \"colds or flus\" (p > 0.05).
UNASSIGNED: CBD was safe and well tolerated in healthy adults. These findings show pain was lower in the CBD group, suggesting a potentially positive effect for consumption of CBD. \"Vigor-activity\" decreased across the intervention, which may be a confounding effect of the academic semester. While the dosage chosen was safe, more research may be warranted using higher doses as these may be needed to observe further therapeutic effects in healthy populations.